UT Southwestern Harold C. Simmons Comprehensive Cancer Center | Strategic Alliance Partners

Praveen Ramakrishnan, MD, MS, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma.

Farrukh Awan, MD, discusses the current use of BTK inhibitors in the management of chronic lymphocytic leukemia and important factors to consider when determining the best treatment strategy.

Praveen Ramakrishnan, MD, MS, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma.

Praveen Ramakrishnan, MD, discusses the negative results from the phase 3 BELINDA trial and its effect on the use of CAR T-cell products in aggressive B-cell non-Hodgkin lymphoma.

Farrukh Awan, MD, discusses new agents under investigation in chronic lymphocytic leukemia and mantle cell lymphoma and emphasizes the importance of weighing each drug’s risks and benefits against individual patient needs and preferences to make informed decisions.

Farrukh Awan, MD, discusses the evolution of treating frontline chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses transplant and chemotherapy options in frontline diffuse large B-cell lymphoma, the emergence of CAR T-cell therapy in relapsed diffuse large B-cell lymphoma, and available targeted therapies in acute myeloid leukemia.

Praveen Ramakrishnan, MD, MS, discusses the evolution of diffuse large B-cell lymphoma treatment, the implications of key phase 3 studies, and how emerging bispecific T-cell engagers and antibody-drug conjugates may increase treatment accessibility beyond the limitations of CAR T-cell therapy for patients at various disease stages.

Sheena Bhalla, MD, discusses the need for improved understanding of EGFR exon 20 insertion mutations in the development of non–small cell lung cancer treatment.

Neil Desai, MD, discusses the investigation of immune checkpoint inhibitors with chemoradiation in urothelial cancer.

Although the efficacy of targeted agents and outcomes for patients with genetic mutations can vary, the availability of these treatments adds to the need for genetic testing across all patients with non–small cell lung cancer.

Neil Desai, MD, discusses the ideal patient for bladder preservation in urothelial cancer.

Neil Desai, MD, discusses the evolving standard of care in urothelial cancer.

Neil Desai, MD, discusses the variety of options available for patients with localized urothelial cancer who are ineligible for cisplatin-based chemoradiation.

Tian Zhang, MD, discusses the benefits of multidisciplinary collaboration, how to select the best agents for each patient, and how treatments such as radiation in RCC and bladder-sparing chemoradiation in urothelial cancer fit into the overall treatment paradigms for these diseases.

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Heather McArthur, MD, MPH, described how the data from DESTINY-Breast03 reshapes the treatment landscape and offers added benefit to patients with brain metastases.

Heather McArthur, MD, MPH, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki for second-line treatment in HER2-positive metastatic breast cancer.

The investigational RNA interference therapy, ARO-HIF2, reduced levels of hypoxia inducible factor-2 alpha expression and had acceptable tolerability when used in patients with clear cell renal cell carcinoma, according to data from the phase 1b AROHIF21001 trial.

Heather McArthur, MD, MPH, discusses key treatment developments in early-stage and metastatic HER2-positive breast cancer and triple-negative breast cancer, plus ongoing research at UT Southwestern Harold C. Simmons Comprehensive Cancer Center.

Research led by UT Southwestern scientists suggests that an investigational drug could restore the ability of some non–small cell lung cancers to respond to an immune checkpoint blockade, a therapy that harnesses the immune system to fight malignant tumors.

Patients who develop post–essential thrombocythemia myelofibrosis or post–polycythemia vera myelofibrosis, which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effective treatment.

Ruben A. Mesa, MD, discusses the unique characteristics of momelotinib in myelofibrosis.

Larry Anderson, MD, PhD, discusses the methods utilized in the phase 2 KarMMa trial in multiple myeloma.

Larry Anderson, MD, PhD, discusses the challenges faced with CAR T-cell therapy in patients with multiple myeloma.

Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.

Nicole Rich, MD, discusses the prevalence of cachexia in hepatocellular carcinoma.

Hans Hammers, MD, PhD,discusses the safety profile of lenvatinib in combination with pembrolizumab in renal cell carcinoma.

Neoadjuvant stereotactic radiation followed by radical nephrectomy and thrombectomy is a safe and feasible treatment option for patients with renal cell carcinoma and inferior vena cava tumor thrombus.

Hans Hammers, MD, PhD, discusses the potential utility of HIF-2α inhibitors in renal cell carcinoma.